Pharma Focus Asia
KP - Sustainable Packaging Solutions

Boehringer Ingelheim Announces US$260 million Investment into new Biologicals Development Center

Introduction:

Boehringer Ingelheim announced a US$260 million investment into a new Biological Development Center (BDC) at the company’s Research and Development site in Biberach, Germany.

Features:

The BDC will help to maximise by integrating Biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit. It provides about 100 member employment at the new BDC.

The BDC is expected to be operational by 2020.

New Biologicals Development Center majorly focuses on therapeutic areas with high unmet medical need such as cancer and immunological diseases.

The BDC will help to maximise by integrating Biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit.

The BDC will be particularly driven by two core areas, immune oncology and immunology.

The new building will employ about 100 new employees.

The BDC is expected to be operational by 2020.

Specifications:

NameBoehringer Ingelheim
LocationBiberach, Germany
TypeConstruction
ScheduleTo be operational by 2020
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?